HETEROCYCLIC JANUS KINASE 3 INHIBITORS

THE PRESENT INVENTION PROVIDES A COMPOUND OF FORMULA (I) HAVING AN EXCELLENT JAK3 INHIBITION ACTIVITY AND BEING USEFUL AS AN ACTIVE INGREDIENT OF AN AGENT FOR TREATING AND/OR PREVENTING VARIOUS IMMUNE DISEASES INCLUDING AUTOIMMUNE DISEASES INFLAMMATORY DISEASES, AND ALLERGIC DISEASES. THE COMPOUND A...

Full description

Saved in:
Bibliographic Details
Main Authors SASAKI HIROSHI, NAKAI KAZUO, TANAKA AKIRA, HIGASHI YASUYUKI, NAKAJIMA YUTAKA, HAMAGUCHI HISAO, MUKOYOSHI KOICHIRO, TAKAHASHI FUMIE, SHIRAKAMI SHOHEI, HATANAKA KEIKO, KUNIKAWA SHIGEKI, INOUE TAKAYUKI
Format Patent
LanguageEnglish
Published 28.06.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:THE PRESENT INVENTION PROVIDES A COMPOUND OF FORMULA (I) HAVING AN EXCELLENT JAK3 INHIBITION ACTIVITY AND BEING USEFUL AS AN ACTIVE INGREDIENT OF AN AGENT FOR TREATING AND/OR PREVENTING VARIOUS IMMUNE DISEASES INCLUDING AUTOIMMUNE DISEASES INFLAMMATORY DISEASES, AND ALLERGIC DISEASES. THE COMPOUND ACCORDING TO THE PRESENT INVENTION HAS AN INHIBITION ACTIVITY AGAINST JAK3 AND IS THUS USEFUL AS AN ACTIVE INGREDIENT OF AN AGENT FOR TREATING OR PREVENTING DISEASES CAUSED BY UNDESIRABLE CYTOKINE SIGNAL TRANSMISSION (E.G., REJECTION DURING ORGAN/TISSUE TRANSPLANTATION, AUTOIMMUNE DISEASES, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, PSORIASIS, ASTHMA, ATOPIC DERMATITIS, ALZHEIMER'S DISEASE, AND ATHEROSCLEROTIC DISEASE), OR DISEASES CAUSED BY ABNORMAL CYTOKINE SIGNAL TRANSMISSION (E.G., CANCER AND LEUKEMIA).
Bibliography:Application Number: MY2008PI02297